Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis

OBJECTIVE: To assess whether secukinumab treatment in patients with active psoriatic arthritis (PsA) is associated with sustained inhibition of radiographic progression. METHODS: In this phase III, double‐blind, placebo‐controlled study, 606 patients with PsA were randomized to receive intravenous (...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Arthritis Rheumatol
Autors principals: van der Heijde, Désirée, Landewé, Robert B., Mease, Philip J., McInnes, Iain B., Conaghan, Philip G., Pricop, Luminita, Ligozio, Greg, Richards, Hanno B., Mpofu, Shephard
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2016
Matèries:
Psoriatic Arthritis
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5129532/
https://ncbi.nlm.nih.gov/pubmed/27014997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.39685
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars